Literature DB >> 17634540

Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.

Anders S Bjartell1, Hikmat Al-Ahmadie, Angel M Serio, James A Eastham, Scott E Eggener, Samson W Fine, Lene Udby, William L Gerald, Andrew J Vickers, Hans Lilja, Victor E Reuter, Peter T Scardino.   

Abstract

PURPOSE: It has been suggested that cysteine-rich secretory protein 3 (CRISP-3) and beta-microseminoprotein (MSP) are associated with outcome in prostate cancer. We investigated whether these markers are related to biochemical recurrence and whether addition of the markers improves prediction of recurring disease. EXPERIMENTAL
DESIGN: Tissue microarrays of radical prostatectomy specimens were analyzed for CRISP-3 and MSP by immunohistochemistry. Associations between marker positivity and postprostatectomy biochemical recurrence [prostate-specific antigen (PSA) >0.2 ng/mL with a confirmatory level] were evaluated by univariate and multivariable Cox proportional hazards regression. Multivariable analyses controlled for preoperative PSA and pathologic stage and grade.
RESULTS: Among 945 patients, 224 had recurrence. Median follow-up for survivors was 6.0 years. Patients positive for CRISP-3 had smaller recurrence-free probabilities, whereas MSP-positive patients had larger recurrence-free probabilities. On univariate analysis, the hazard ratio for patients positive versus negative for CRISP-3 was 1.53 (P=0.010) and for MSP was 0.63 (P=0.004). On multivariable analysis, both CRISP-3 (P=0.007) and MSP (P=0.002) were associated with recurrence. The hazard ratio among CRISP-3-positive/MSP-negative patients compared with CRISP-3-negative/MSP-positive patients was 2.38. Adding CRISP-3 to a base model that included PSA and pathologic stage and grade did not enhance the prediction of recurrence, but adding MSP increased the concordance index minimally from 0.778 to 0.781.
CONCLUSION: We report evidence that CRISP-3 and MSP are independent predictors of recurrence after radical prostatectomy for localized prostate cancer. However, addition of the markers does not importantly improve the performance of existing predictive models. Further research should aim to elucidate the functions of CRISP-3 and MSP in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17634540      PMCID: PMC2660867          DOI: 10.1158/1078-0432.CCR-06-3031

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  51 in total

1.  Identification of disease-specific genes in chronic pancreatitis using DNA array technology.

Authors:  H Friess; J Ding; J Kleeff; Q Liao; P O Berberat; J Hammer; M W Büchler
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

2.  Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer.

Authors:  Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Eric Klein; Patrick A Kupelian; David I Quinn; Susan M Henshall; John J Grygiel; Robert L Sutherland; Phillip D Stricker; Jean de Kernion; Thomas Cangiano; Fritz H Schröder; Mark F Wildhagen; Peter T Scardino; Michael W Kattan
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

3.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

4.  An ELISA for SGP28/CRISP-3, a cysteine-rich secretory protein in human neutrophils, plasma, and exocrine secretions.

Authors:  Lene Udby; Jack B Cowland; Anders H Johnsen; Ole E Sørensen; Niels Borregaard; Lars Kjeldsen
Journal:  J Immunol Methods       Date:  2002-05-01       Impact factor: 2.303

5.  In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates.

Authors:  P S Chan; L W Chan; J W Xuan; J L Chin; H L Choi; F L Chan
Journal:  Prostate       Date:  1999-10-01       Impact factor: 4.104

6.  Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.

Authors:  P Siivola; K Pettersson; T Piironen; T Lövgren; H Lilja; A Bjartell
Journal:  Urology       Date:  2000-10-01       Impact factor: 2.649

7.  Immunohistochemical localization of a prostatic secretory protein of 94 amino acids in normal prostatic tissue, in primary prostatic tumors and in their metastases.

Authors:  J Y Dubé; G Pelletier; P Gagnon; R R Tremblay
Journal:  J Urol       Date:  1987-10       Impact factor: 7.450

8.  Cysteine-rich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma.

Authors:  Lene Udby; Ole E Sørensen; Jesper Pass; Anders H Johnsen; Niels Behrendt; Niels Borregaard; Lars Kjeldsen
Journal:  Biochemistry       Date:  2004-10-12       Impact factor: 3.162

9.  Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.

Authors:  Borhane Annabi; Mounia Bouzeghrane; Jean-Christophe Currie; Hélène Dulude; Luc Daigneault; Seema Garde; Shafaat A Rabbani; Chandra Panchal; Jinzi J Wu; Richard Béliveau
Journal:  Anticancer Drugs       Date:  2006-04       Impact factor: 2.248

10.  Isolation and characterization of the androgen-dependent mouse cysteine-rich secretory protein-3 (CRISP-3) gene.

Authors:  U Schwidetzky; B Haendler; W D Schleuning
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

View more
  38 in total

1.  Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Authors:  Hong Lou; Hongchuan Li; Meredith Yeager; Kate Im; Bert Gold; Thomas D Schneider; Joseph F Fraumeni; Stephen J Chanock; Stephen K Anderson; Michael Dean
Journal:  Hum Genet       Date:  2012-06-04       Impact factor: 4.132

Review 2.  The role of cysteine-rich secretory proteins in male fertility.

Authors:  Adam J Koppers; Thulasimala Reddy; Moira K O'Bryan
Journal:  Asian J Androl       Date:  2010-10-25       Impact factor: 3.285

3.  Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3.

Authors:  Aleyde Van Eynde; Kirill Litovkin; Mathieu Bollen
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

4.  Growth inhibition mediated by PSP94 or CRISP-3 is prostate cancer cell line specific.

Authors:  Bhakti R Pathak; Ananya A Breed; Vaishali H Nakhawa; Dhanashree D Jagtap; Smita D Mahale
Journal:  Asian J Androl       Date:  2010-08-02       Impact factor: 3.285

Review 5.  Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography.

Authors:  Timothy R Rebbeck
Journal:  Semin Radiat Oncol       Date:  2016-08-26       Impact factor: 5.934

6.  Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.

Authors:  Mesude Bicak; Xing Wang; Xiaoni Gao; Xing Xu; Riina-Minna Väänänen; Pekka Taimen; Hans Lilja; Kim Pettersson; Robert J Klein
Journal:  Hum Mol Genet       Date:  2020-06-27       Impact factor: 6.150

Review 7.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

8.  Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.

Authors:  Hong Lou; Meredith Yeager; Hongchuan Li; Jesus Gonzalez Bosquet; Richard B Hayes; Nick Orr; Kai Yu; Amy Hutchinson; Kevin B Jacobs; Peter Kraft; Sholom Wacholder; Nilanjan Chatterjee; Heather Spencer Feigelson; Michael J Thun; W Ryan Diver; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Jing Ma; J Michael Gaziano; Meir Stampfer; Fredrick R Schumacher; Edward Giovannucci; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Stephen K Anderson; Margaret Tucker; Robert N Hoover; Joseph F Fraumeni; Gilles Thomas; David J Hunter; Michael Dean; Stephen J Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-21       Impact factor: 11.205

9.  Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

Authors:  Barbara Wegiel; Thomas Jiborn; Magnus Abrahamson; Leszek Helczynski; Leo Otterbein; Jenny Liao Persson; Anders Bjartell
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

10.  Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer.

Authors:  Meredith Yeager; Zuoming Deng; Joseph Boland; Casey Matthews; Jennifer Bacior; Victor Lonsberry; Amy Hutchinson; Laura A Burdett; Liqun Qi; Kevin B Jacobs; Jesus Gonzalez-Bosquet; Sonja I Berndt; Richard B Hayes; Robert N Hoover; Gilles Thomas; David J Hunter; Michael Dean; Stephen J Chanock
Journal:  Hum Genet       Date:  2009-12       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.